A Phase 1, Two-part, Open-label Dose-escalation and Double-blind, Placebo-controlled Dose-expansion Study with an Open-label Extension to Evaluate the Safety and Efficacy of ATA188 in Subjects with Progressive Multiple Sclerosis (ATA188-MS-101
Details
Age
Adult
Type of Study
Treatment
Locations
Brain Imaging Center (BIC)
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
Enrique Alvarez, MD, PhD
Study ID
Protocol Number: 20-0454
More information available at ClinicalTrials.gov: NCT03283826
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers